LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells
Takahiro Yamazaki, Erik Wennerberg, Michal Hensler, Aitziber Buqué, Jeffrey Kraynak, Jitka Fucikova, Xi Kathy Zhou, Baldur Sveinbjørnsson, Øystein Rekdal, Sandra Demaria & Lorenzo Galluzzial
OncoImmunology, Volume 10, 2021 - Issue 1
Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors
James Spicer, Aurelien Marabelle, Jean-Francois Baurain, Nina Louise Jebsen, Dag Erik Jøssang, Ahmad Awada, Rebecca Kristeleit, Delphine Loirat, George Lazaridis, Christiane Jungels, Paal Brunsvig, Berit Nicolaisen, Andrew Saunders, Hamina Patel, Jerôme Galon, Fabienne Hermitte, Ketil Andre Camilio, Brynjar Mauseth, Vibeke Sundvold, Baldur Sveinbjørnsson and Øystein Rekdal
Clinical Cancer Research 2021
Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
Karianne Giller Fleten, J Johannes Eksteen, Brynjar Mauseth, Ketil André Camilio, Terje Vasskog, Baldur Sveinbjørnsson, Øystein Rekdal, Gunhild M Mælandsmo, Kjersti Flatmark
Sci Rep. 2021 Mar 24
Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides
Ilio Vitale, Takahiro Yamazaki, Erik Wennerberg, Baldur Sveinbjørnsson, Øystein Rekdal, Sandra Demaria, Lorenzo Galluzzi
Trends in Cancer (2021)
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Lorenzo Galluzzi, Ilio Vitale, Sarah Warren, Sandy Adjemian, Patrizia Agostinis, Aitziber Buqué Martinez, Timothy A Chan, George Coukos, Sandra Demaria, Eric Deutsch, Dobrin Draganov, Richard L Edelson, Silvia C Formenti, Jitka Fucikova, Lucia Gabriele, Udo S Gaipl, Sofia R Gameiro, Abhishek D Garg, Encouse Golden, Jian Han, Kevin J Harrington, Akseli Hemminki, James W Hodge, Dewan Md Sakib Hossain, Tim Illidge, Michael Karin, Howard L Kaufman, Oliver Kepp, Guido Kroemer, Juan Jose Lasarte, Sherene Loi, Michael T Lotze, Gwenola Manic, Taha Merghoub, Alan A Melcher, Karen L Mossman, Felipe Prosper, Øystein Rekdal, Maria Rescigno, Chiara Riganti, Antonella Sistigu, Mark J Smyth, Radek Spisek, John Stagg, Bryan E Strauss, Daolin Tang, Kazuki Tatsuno, Stefaan W van Gool, Peter Vandenabeele, Takahiro Yamazaki, Dmitriy Zamarin, Laurence Zitvogel, Alessandra Cesano, Francesco M Marincola.
Journal for ImmunoTherapy of Cancer (2020, Volume 8, Issue 1)
LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects
Hsin-Wei Liao, Christopher Garris, Christina Pfirschke, Steffen Rickelt, Sean Arlauckas, Marie Siwicki,
Rainer H. Kohler, Ralph Weissleder, Vibeke Sundvold Gjerstad, Baldur Sveinbjørnsson, Øystein
Rekdal and Mikael J. Pittet
Cell Stress (2019)
Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report
Nina Louise Jebsen, Torunn Oveland Apelseth, Hans Kristian Haugland, Øystein Rekdal, Hamina Patel, Bjørn Tore Gjertsen and Dag Eirik Jøssang
Journal of Medical Case Reports (2019) 13:177
The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma
Brynjar Mauseth, Ketil André Camilio, Jihua Shi, Clara Louise Hammarström, Øystein Rekdal, Baldur Sveinbjørnsson, and Pål-Dag Line
Molecular Therapy: Oncolytics Vol. 14 September 2019
Tumor lysis with LTX-401 creates anticancer immunity
Wei Xie, Laura Mondragón, Brynjar Mauseth, Yan Wang, Jonathan Pol, Sarah Lévesque, Heng Zhou, Takahiro Yamazaki, Johannes J. Eksteen, Laurence Zitvogel, Baldur Sveinbjørnsson, Øystein Rekdal, Oliver Kepp & Guido Kroemer
OncoImmunology, published online 13 Apr 2019 (https://www.tandfonline.com/doi/full/10.1080/2162402X.2019.1594555)  
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
Ketil A. Camilio, Meng-Yu Wang, Brynjar Mauseth, Stein Waagene, Gunnar Kvalheim, Øystein Rekdal, Baldur Sveinbjørnsson and Gunhild M. Mælandsmo
Camilio et al. Breast Cancer Research (2019) 21:9

Oncolytic peptide LTX-315 induces an immunemediated abscopal effect in a rat sarcoma model
J. Nestvold, Meng-Yu Wang, K. A. Camilio, S. Zinöcker, T. E. Tjelle, A. Lindberg, B. E. Haug, G. Kvalheim, B. Sveinbjørnsson & Ø. Rekdal
OncoImmunology, Volume 6, 2017 - Issue 8
LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment
B. Sveinbjørnsson, K. A. Camilio, B. E. Haug & Ø. Rekdal
Future Medicinal Chemistry 2017 Published Online: May 11th, 2017.  
LTX-315, CAPtivating immunity with necrosis
Antonella Sistigu, Gwenola Manic, and Ilio Vitale
Cell Cycle 2016, Vol 15, NO.9, 1176-1177.
The oncolytic compound LTX-401 targets the Golgi apparatus
H Zhou, A Sauvat, LC Gomes-da-Silva, S Durand, S Forveille, K Iribarren, T Yamazaki, S Souquere, L Bezu, K Müller, M Leduc, P Liu, L Zhao, A Marabelle, L Zitvogel, Ø Rekdal, O Kepp and G Kroemer
Cell Death and Differentiation (2016), 1-11.
The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade
T Yamazaki, JM Pitt, M Vétizou, A Marabelle, C Flores, Ø Rekdal, G Kroemer and L Zitvogel
Cell Death and Differentiation (2016), 1-12.
Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide
Bengt Erik Haug, Ketil André Camilio, Liv Tone Eliassen, Wenche Stensen, John Sigurd Svendsen, Kristel Berg, Bjarte Mortensen, Guillaume Serin, Jean-Francois Mirjolet, Francis Bichat and Øystein Rekdal
Journal of Medicinal Chemistry 2016.
The oncolytic peptide LTX-315 triggers immunogenic cell death
H Zhou, S Forveille, A Sauvat, T Yamazaki, L Senovilla, Y Ma, P Liu, H Yang, L Bezu, K Müller, L Zitvogel, Ø Rekdal, O Kepp and G Kroemer
Cell Death and Disease (2016) 7.
The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells
Liv-Marie Eike, Nannan Yang, Øystein Rekdal and Baldur Sveinbjørnsson
Oncotarget, October 13, 2015.
The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization
Heng Zhou, Sabrina Forveille, Allan Sauvat, Valentina Sica, Valentina Izzo, Sylvère Durand, Kevin Müller, Peng Liu, Laurence Zitvogel, Øystein Rekdal, Oliver Kepp and Guido Kroemer
Oncotarget, September 10, 2015.
LTX-315 (OncoporeTM)_A short synthetic anticancer peptide and novel immunotherapeutic agent
K. A. Camilio, Ø. Rekdal, B. Sveinbjörnsson
OncoImmunology 3, e29181; June 201 4; 2014 Landes Bioscience.
Complete regression and systemic protective immune reponses obtained in B16 melanomas after treatment with LTX-315
K. A. Camilio, G. Berge, C. S. Ravuri, Ø. Rekdal, B. Sveinbjörnsson
Cancer Immunology, Immunotherapy: Volume 63, Issue 6 (2014), Page 601-613.
Oral presentation at AASLD, The Liver Meeting 2013
PD Line, J Shi, JM Nestvold, MY Wang, G Kvalheim, Ø Rekdal
A novel immunotherapeutic treatment for experimental hepatocellular carcinoma (HCC) using the host-defense derived peptide LTX-315.
Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity
Rekdal Ø, Haug BE, Kalaaji M, Hunter HN, Lindin I, Israelsson I, Solstad T, Yang N, Brandl M, Mantzilas D, Vogel HJ
J Biol Chem. 2012 Jan 2;287(1):233-44. Epub 2011 Nov 4.
Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells
Fadnes B, Uhlin-Hansen L, Lindin I, Rekdal Ø
BMC Cancer. 2011 Mar 31;11:116.
Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide
Berge G, Eliassen LT, Camilio KA, Bartnes K, Sveinbjørnsson B & Rekdal Ø
Cancer Immunol Immunother 59: 1285-94, 2010.
The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells
Fadnes B, Rekdal Ø & Uhlin-Hansen L
BMC Cancer 9: 183, 2009.
The antimicrobial peptide, Lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo
L. T. Eliassen, G. Berge, A. Leknessund, M. Wikman, I. Lindin, C. Løkke, F.Ponthan, J. I. Johnsen, B. Sveinbjørnsson, P Kogner, T. Flægstad and Ø. Rekdal
Int. J of Cancer. 119. 493-500. (2006).
The effects of shortening lactoferrin derived peptides against tumor cells, bacteria and normal human cells
N. Yang, M.B. Strøm, S.M. Mekonnen, J.S. Svendsen and Ø. Rekdal
J. Peptide Sci. 10 (2004) 37.
Enhanced antitumor activity of 15-residue bovine lactoferricin derivatives containing bulky aromatic amino acids ad lipophilic N-terminal modifications
L.T. Eliassen, B.E. Haug, G. Berge and Ø. Rekdal
J. Peptide Sci . 9 (2003) 510-517.
Antitumor activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptides
N. Yang, T. Lejon and Ø. Rekdal
J. Peptide Sci. 9 (2003) 300.
Enhanced antitumor activity and selectivity of lactoferrin derived peptides
N. Yang, W. Stensen, J. S. Svendsen and Ø.Rekdal
J. Peptide Res. 60 (2002) 187.
Evidence for a Direct Antitumor Mechanism of Action of Bovine Lactoferricin
L.T. Eliassen, G. Berge, B. Sveinbjørnsson, J.S. Svendsen, L.H. Vorland and Ø. Rekdal
Anticancer Res. 22 (2002) 2703.